A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
Completed · Phase 1
Conditions studied: Dravet Syndrome, Lennox Gastaut Syndrome
In brief
This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).
Key facts
- Study ID
- NCT03467113
- Run by
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- People needed
- 9
- Starts
- 2018-01-19
- Expected to finish
- 2020-06-24
- Last updated by the study team
- 2023-12-01
Who can join
Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- PANDA Neurology/CIRCA — Atlanta, Georgia, United States
- MultiCare Institute for Research & Innovation — Tacoma, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.